1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Hong, M. Cady, S.D. Mishanina, T.V. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C10 H17 N 151.249 (3S,5S,7S)-tricyclo[3.3.1.1~3,7~]decan-1-amine Amantadine non-polymer C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking UK J.Mol.Biol. JMOBAK 0070 0022-2836 385 1127 1141 10.1016/j.jmb.2008.11.022 19061899 Structure of amantadine-bound M2 transmembrane peptide of influenza A in lipid bilayers from magic-angle-spinning solid-state NMR: the role of Ser31 in amantadine binding. 2009 US Proc.Natl.Acad.Sci.USA PNASA6 0040 0027-8424 105 1483 1488 10.1073/pnas.0711500105 18230730 Amantadine-induced conformational and dynamical changes of the influenza M2 transmembrane proton channel. 2008 US J.Phys.Chem.B JPCBFK 1278 1089-5647 111 10825 10832 10.1021/jp073823k 17705425 Side-chain conformation of the M2 transmembrane peptide proton channel of influenza a virus from 19F solid-state NMR. 2007 US J.Am.Chem.Soc. JACSAT 0004 0002-7863 128 7242 7251 10.1021/ja0603406 16734478 Determination of the oligomeric number and intermolecular distances of membrane protein assemblies by anisotropic 1H-driven spin diffusion NMR spectroscopy. 2006 10.2210/pdb2kad/pdb pdb_00002kad 2688.215 Transmembrane peptide of Matrix protein 2 Transmembrane peptide of influenza A M2 protein: UNP residues 22-46 4 syn polymer 151.249 (3S,5S,7S)-tricyclo[3.3.1.1~3,7~]decan-1-amine 1 syn non-polymer Proton channel protein M2 no no SSDPLVVAASIIGILHLIAWILDRL SSDPLVVAASIIGILHLIAWILDRL A,B,C,D polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n 13C and 15N chemical shifts of DLPC-bound M2(22-46) measured by solid-state NMR. database_2 pdbx_nmr_software pdbx_nmr_spectrometer pdbx_struct_assembly pdbx_struct_oper_list struct_ref_seq_dif struct_site repository Initial release Version format compliance Data collection Database references Derived calculations 1 0 2008-11-18 1 1 2011-07-13 1 2 2021-10-20 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_nmr_software.name _pdbx_nmr_spectrometer.model _struct_ref_seq_dif.details _struct_site.pdbx_auth_asym_id _struct_site.pdbx_auth_comp_id _struct_site.pdbx_auth_seq_id BMRB Y RCSB 2008-11-04 REL REL 308 (3S,5S,7S)-tricyclo[3.3.1.1~3,7~]decan-1-amine Solid phase peptide synthesis sample structures with the least restraint violations 1 1 2D 13C-13C DQF_COSY 2D 15N-13C HETCOR 2D DARR 2D INADEQUATE 4-6 mg/mL Selective U-13C, 15N labeled 15-25 mg/mL 10 mM 0.1 mM 1 mM 20-25 mg/mL 7.5 ambient 243 K TALOS torsion angle dynamics 1 fewest violations 4-6 mg/mL Selective U-13C, 15N labeled M2 Transmembrane Peptide, 15-25 mg/mL DLPC, 10 mM sodium phosphate, 0.1 mM sodium azide, 1 mM EDTA, 20-25 mL H2O, Solid-State NMR: Hydrated DLPC gel, approx. 50% H2O by weight. DLPC:M2TMP:Amantadine 15:1:8 Solid-State NMR: Hydrated DLPC gel, approx. 50% H2O by weight. DLPC:M2TMP:Amantadine 15:1:8 Bruker Biospin collection TopSpin 1.3 Accelrys Software Inc. structure solution Insight II 2005 Accelrys Software Inc. refinement Insight II 2005 600 Bruker AVANCE Bruker AVANCE 400 Bruker DRX Bruker DRX 308 1 2 308 308 1 A SER 22 n 1 SER 22 A SER 23 n 2 SER 23 A ASP 24 n 3 ASP 24 A PRO 25 n 4 PRO 25 A LEU 26 n 5 LEU 26 A VAL 27 n 6 VAL 27 A VAL 28 n 7 VAL 28 A ALA 29 n 8 ALA 29 A ALA 30 n 9 ALA 30 A SER 31 n 10 SER 31 A ILE 32 n 11 ILE 32 A ILE 33 n 12 ILE 33 A GLY 34 n 13 GLY 34 A ILE 35 n 14 ILE 35 A LEU 36 n 15 LEU 36 A HIS 37 n 16 HIS 37 A LEU 38 n 17 LEU 38 A ILE 39 n 18 ILE 39 A ALA 40 n 19 ALA 40 A TRP 41 n 20 TRP 41 A ILE 42 n 21 ILE 42 A LEU 43 n 22 LEU 43 A ASP 44 n 23 ASP 44 A ARG 45 n 24 ARG 45 A LEU 46 n 25 LEU 46 A SER 22 n 1 SER 22 B SER 23 n 2 SER 23 B ASP 24 n 3 ASP 24 B PRO 25 n 4 PRO 25 B LEU 26 n 5 LEU 26 B VAL 27 n 6 VAL 27 B VAL 28 n 7 VAL 28 B ALA 29 n 8 ALA 29 B ALA 30 n 9 ALA 30 B SER 31 n 10 SER 31 B ILE 32 n 11 ILE 32 B ILE 33 n 12 ILE 33 B GLY 34 n 13 GLY 34 B ILE 35 n 14 ILE 35 B LEU 36 n 15 LEU 36 B HIS 37 n 16 HIS 37 B LEU 38 n 17 LEU 38 B ILE 39 n 18 ILE 39 B ALA 40 n 19 ALA 40 B TRP 41 n 20 TRP 41 B ILE 42 n 21 ILE 42 B LEU 43 n 22 LEU 43 B ASP 44 n 23 ASP 44 B ARG 45 n 24 ARG 45 B LEU 46 n 25 LEU 46 B SER 22 n 1 SER 22 C SER 23 n 2 SER 23 C ASP 24 n 3 ASP 24 C PRO 25 n 4 PRO 25 C LEU 26 n 5 LEU 26 C VAL 27 n 6 VAL 27 C VAL 28 n 7 VAL 28 C ALA 29 n 8 ALA 29 C ALA 30 n 9 ALA 30 C SER 31 n 10 SER 31 C ILE 32 n 11 ILE 32 C ILE 33 n 12 ILE 33 C GLY 34 n 13 GLY 34 C ILE 35 n 14 ILE 35 C LEU 36 n 15 LEU 36 C HIS 37 n 16 HIS 37 C LEU 38 n 17 LEU 38 C ILE 39 n 18 ILE 39 C ALA 40 n 19 ALA 40 C TRP 41 n 20 TRP 41 C ILE 42 n 21 ILE 42 C LEU 43 n 22 LEU 43 C ASP 44 n 23 ASP 44 C ARG 45 n 24 ARG 45 C LEU 46 n 25 LEU 46 C SER 22 n 1 SER 22 D SER 23 n 2 SER 23 D ASP 24 n 3 ASP 24 D PRO 25 n 4 PRO 25 D LEU 26 n 5 LEU 26 D VAL 27 n 6 VAL 27 D VAL 28 n 7 VAL 28 D ALA 29 n 8 ALA 29 D ALA 30 n 9 ALA 30 D SER 31 n 10 SER 31 D ILE 32 n 11 ILE 32 D ILE 33 n 12 ILE 33 D GLY 34 n 13 GLY 34 D ILE 35 n 14 ILE 35 D LEU 36 n 15 LEU 36 D HIS 37 n 16 HIS 37 D LEU 38 n 17 LEU 38 D ILE 39 n 18 ILE 39 D ALA 40 n 19 ALA 40 D TRP 41 n 20 TRP 41 D ILE 42 n 21 ILE 42 D LEU 43 n 22 LEU 43 D ASP 44 n 23 ASP 44 D ARG 45 n 24 ARG 45 D LEU 46 n 25 LEU 46 D author_defined_assembly 4 tetrameric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 1 B D HB1 HG13 ALA ILE 30 35 0.89 1 A D HG13 HB1 ILE ALA 35 30 0.93 1 B C HG13 HB1 ILE ALA 35 30 0.95 1 A C HB1 HG13 ALA ILE 30 35 0.99 1 A C O HD13 ALA ILE 30 35 1.42 1 A D HD13 O ILE ALA 35 30 1.43 1 B D O HD12 ALA ILE 30 35 1.47 1 B C HD13 O ILE ALA 35 30 1.49 1 A D HD12 O ILE ALA 35 30 1.49 1 B C HD12 O ILE ALA 35 30 1.50 1 B D O HD13 ALA ILE 30 35 1.50 1 A C O HD12 ALA ILE 30 35 1.52 1 A C HE2 CE2 HIS TRP 37 41 1.55 1 B C CE2 HE2 TRP HIS 41 37 1.55 1 A D HD21 ND1 LEU HIS 38 37 1.60 1 A D CD1 O ILE ALA 35 30 1.72 1 A C O CD1 ALA ILE 30 35 1.73 1 B D O CD1 ALA ILE 30 35 1.73 1 B C CD1 O ILE ALA 35 30 1.74 1 B C CD2 NE2 TRP HIS 41 37 1.95 1 A C NE2 CD2 HIS TRP 37 41 1.96 1 B D NE2 CD2 HIS TRP 37 41 2.04 1 A D CD2 NE2 TRP HIS 41 37 2.05 1 A C CD2 CZ3 HIS TRP 37 41 2.11 1 B C CZ3 CD2 TRP HIS 41 37 2.15 1 A D CZ3 CD2 TRP HIS 41 37 2.19 1 6.76 0.90 118.30 125.06 A A A CB CG OD1 ASP ASP ASP 24 24 24 N 1 7.61 0.90 118.30 125.91 A A A CB CG OD1 ASP ASP ASP 44 44 44 N 1 -6.60 0.90 118.30 111.70 A A A CB CG OD2 ASP ASP ASP 44 44 44 N 1 -3.16 0.50 120.30 117.14 A A A NE CZ NH2 ARG ARG ARG 45 45 45 N 1 6.68 0.90 118.30 124.98 B B B CB CG OD1 ASP ASP ASP 24 24 24 N 1 7.59 0.90 118.30 125.89 B B B CB CG OD1 ASP ASP ASP 44 44 44 N 1 -6.61 0.90 118.30 111.69 B B B CB CG OD2 ASP ASP ASP 44 44 44 N 1 -3.20 0.50 120.30 117.10 B B B NE CZ NH2 ARG ARG ARG 45 45 45 N 1 6.74 0.90 118.30 125.04 C C C CB CG OD1 ASP ASP ASP 24 24 24 N 1 7.55 0.90 118.30 125.85 C C C CB CG OD1 ASP ASP ASP 44 44 44 N 1 -6.53 0.90 118.30 111.77 C C C CB CG OD2 ASP ASP ASP 44 44 44 N 1 -3.31 0.50 120.30 116.99 C C C NE CZ NH2 ARG ARG ARG 45 45 45 N 1 6.69 0.90 118.30 124.99 D D D CB CG OD1 ASP ASP ASP 24 24 24 N 1 7.53 0.90 118.30 125.83 D D D CB CG OD1 ASP ASP ASP 44 44 44 N 1 -6.56 0.90 118.30 111.74 D D D CB CG OD2 ASP ASP ASP 44 44 44 N 1 -3.23 0.50 120.30 117.07 D D D NE CZ NH2 ARG ARG ARG 45 45 45 N 1 A A C OXT LEU LEU 46 46 -0.139 0.019 1.229 1.090 N 1 B B C OXT LEU LEU 46 46 -0.139 0.019 1.229 1.090 N 1 C C C OXT LEU LEU 46 46 -0.137 0.019 1.229 1.092 N 1 D D C OXT LEU LEU 46 46 -0.140 0.019 1.229 1.089 N 13C and 15N chemical shifts of DLPC-bound M2(22-46) measured by solid-state NMR. Magic-Angle-Spinning Solid-State NMR Structure of Influenza A M2 Transmembrane Domain 1 N N 1 N N 1 N N 1 N N 2 N N A SER 22 A SER 1 HELX_P A LEU 46 A LEU 25 1 1 25 B SER 22 B SER 1 HELX_P B LEU 46 B LEU 25 1 2 25 C SER 22 C SER 1 HELX_P C LEU 46 C LEU 25 1 3 25 D SER 22 D SER 1 HELX_P D LEU 46 D LEU 25 1 4 25 MEMBRANE PROTEIN transmembrane helix, proton channel, lipid bilayers, influenza A, Alternative splicing, Hydrogen ion transport, Ion transport, Ionic channel, Lipoprotein, Palmitate, Phosphoprotein, Signal-anchor, Transport, Virion, MEMBRANE PROTEIN M2_I97A1 UNP 1 22 O70632 SSDPLVVAASIIGILHLILWILDRL 22 46 2KAD 22 46 O70632 A 1 1 25 22 46 2KAD 22 46 O70632 B 1 1 25 22 46 2KAD 22 46 O70632 C 1 1 25 22 46 2KAD 22 46 O70632 D 1 1 25 1 LEU engineered mutation ALA 40 2KAD A O70632 UNP 40 19 2 LEU engineered mutation ALA 40 2KAD B O70632 UNP 40 19 3 LEU engineered mutation ALA 40 2KAD C O70632 UNP 40 19 4 LEU engineered mutation ALA 40 2KAD D O70632 UNP 40 19 BINDING SITE FOR RESIDUE 308 A 1 A 308 1 Software 5 A ALA 30 A ALA 9 5 1_555 A SER 31 A SER 10 5 1_555 A GLY 34 A GLY 13 5 1_555 B ALA 30 B ALA 9 5 1_555 B SER 31 B SER 10 5 1_555